| AWK |
Report |
Q2 2026 Adjusted EPS |
IN-LINE |
pred ~$1.51 vs. cons ~$1.52 |
MEDIUM |
| AWK |
Report |
Q2 2026 Operating Revenue |
IN-LINE |
pred ~$1.29B vs. cons ~$1.28B |
LOW |
| AWK |
Report |
YTD authorized new annualized revenue (rate-case execution) |
BEAT |
pred ~$164M vs. prior/cons ~$89M |
MEDIUM |
| AWK |
Guide |
FY2026 Adjusted EPS guidance |
UNCHANGED |
guide ~$6.02-$6.12 (mid $6.07) vs. cons ~$6.07 (FY2026) |
HIGH |
| AWK |
Guide |
Long-term EPS & dividend CAGR through 2030 |
UNCHANGED |
guide ~7-9% vs. cons ~8% (2026-2030) |
HIGH |
| AWK |
Guide |
Essential Utilities merger timing / regulatory path |
UNKNOWN |
guide ~close end-Q1'27 (7 states) vs. cons ~end-Q1'27 (through 1Q27) |
MEDIUM |
| AWK |
Guide |
2026 capital investment plan |
UNCHANGED |
guide ~$3.7B vs. cons ~$3.7B (FY2026) |
LOW |
| AWK |
Return |
Day-1 residual (stock − beta × S&P 500) |
-0.7% |
— |
MEDIUM |
| AWK |
Return |
5-day cumulative residual |
-1.5% (FADE) |
This is a deliberately H2-weighted quarter, so an in-line Q2 (~$1.51) plus a mere reaffirmation of $6.02-6.12 delivers no upward estimate revisions — out-period math stays flat, not raised. The biggest de-risking event (PA $74.9M) resolved July 16 and is already in the price, and shares rallied ~14% off the June low with a +2.6% idiosyncratic pop into the print on 7/28. With the positive catalyst pre-spent and lingering merger dilution/fixed-exchange-ratio and equity-need overhangs, the low-beta defensive name is set up for a 'sell-the-news' fade absent a positive merger/CAMT-equity surprise. Fade is capped by low utility volatility and the constructive PA/rate-case backdrop. |
MEDIUM |